Cargando…

Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients

BACKGROUND: We present our experience of therapeutic vaccination using dendritic cells (DC) pulsed with autologous tumor antigens in patients with advanced melanoma. METHODS: Twenty-one pretreated advanced melanoma patients were vaccinated with autologous DC pulsed with 100 μg/ml of autologous-tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ridolfi, Ruggero, Petrini, Massimiliano, Fiammenghi, Laura, Stefanelli, Monica, Ridolfi, Laura, Ballardini, Michela, Migliori, Giuseppe, Riccobon, Angela
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1562447/ https://www.ncbi.nlm.nih.gov/pubmed/16914047 http://dx.doi.org/10.1186/1479-5876-4-36

Ejemplares similares

Evaluation of in vivo labelled dendritic cell migration in cancer patients
por: Ridolfi, Ruggero, et al.
Publicado: (2004)

Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis
por: Ridolfi, Laura, et al.
Publicado: (2010)

Erratum to “Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis”
por: Ridolfi, Laura, et al.
Publicado: (2011)

FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy
por: Fiammenghi, Laura, et al.
Publicado: (2010)

Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4(+)CD25(++)Foxp3(+) regulatory T-cells in advanced melanoma patients
por: Ridolfi, Laura, et al.
Publicado: (2013)

Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised “proof-of-principle” phase II study
por: de Rosa, Francesco, et al.
Publicado: (2014)

Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial)
por: Ridolfi, Laura, et al.
Publicado: (2018)

The Renewal of Cancer Immunotherapy
por: Bulgarelli, Jenny, et al.
Publicado: (2023)

Dendritic Cell Vaccination in Metastatic Melanoma Turns “Non-T Cell Inflamed” Into “T-Cell Inflamed” Tumors
por: Bulgarelli, Jenny, et al.
Publicado: (2019)

Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response
por: Ridolfi, Laura, et al.
Publicado: (2014)

Stability Program in Dendritic Cell Vaccines: A “Real-World” Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center
por: Pancisi, Elena, et al.
Publicado: (2022)

Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2
por: De Paola, F, et al.
Publicado: (2003)

Potency Assessment of Dendritic Cell Anticancer Vaccine: Validation of the Co-Flow DC Assay
por: Carloni, Silvia, et al.
Publicado: (2021)

Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial
por: Guida, Michele, et al.
Publicado: (2003)

Inconsistency between overall and subgroup analyses
por: Wang, Hongyue, et al.
Publicado: (2022)

DCLK1 immunoreactivity in colorectal neoplasia
por: Gagliardi, Giuseppe, et al.
Publicado: (2012)

Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens
por: Chiarion-Sileni, V, et al.
Publicado: (2011)

Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome
por: Hammarsten, Peter, et al.
Publicado: (2019)

Introduction to the Standard Model (2/10)
por: Ridolfi, Gabriel
Publicado: (2000)

Introduction to the Standard Model (3/10)
por: Ridolfi, Gabriel
Publicado: (2000)

Introduction to the Standard Model (4/10)
por: Ridolfi, Gabriel
Publicado: (2000)

Introduction to the Standard Model (5/10)
por: Ridolfi, Gabriel
Publicado: (2000)

Introduction to the Standard Model (6/10)
por: Ridolfi, Gabriel
Publicado: (2000)

Introduction to the Standard Model (7/10)
por: Ridolfi, Gabriel
Publicado: (2000)

Introduction to the Standard Model (8/10)
por: Ridolfi, Gabriel
Publicado: (2000)

Introduction to the Standard Model (9/10)
por: Ridolfi, Gabriel
Publicado: (2000)

Introduction to the Standard Model (10/10)
por: Ridolfi, Gabriel
Publicado: (2000)

Introduction to the Standard Model (1/10)
por: Ridolfi, Gabriel
Publicado: (2000)

An Introduction to the Standard Theory of Electroweak Interactions (1/4)
por: Ridolfi, Giovanni
Publicado: (2011)

An Introduction to the Standard Theory of Electroweak Interactions (2/4)
por: Ridolfi, Giovanni
Publicado: (2011)

An Introduction to the Standard Theory of Electroweak Interactions (3/4)
por: Ridolfi, Giovanni
Publicado: (2011)

An Introduction to the Standard Theory of Electroweak Interactions (4/4)
por: Ridolfi, Giovanni
Publicado: (2011)

Heavy quark production: recent developments
por: Ridolfi, G
Publicado: (1997)

Properties of $Z^{0} \to h^{0}\gamma$
por: Ridolfi, G
Publicado: (1992)

Search for the Higgs boson: theoretical perspectives
por: Ridolfi, Giovanni
Publicado: (2001)

Biomonitoring of Metals in Children Living in an Urban Area and Close to Waste Incinerators
por: Di Ciaula, Agostino, et al.
Publicado: (2020)

Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma
por: Bulgarelli, Jenny, et al.
Publicado: (2021)

Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients
por: Adamik, Juraj, et al.
Publicado: (2023)

Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?
por: Matteucci, Laura, et al.
Publicado: (2023)

The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9hoeo56lhvfb9r63sscm2pu1e3